Compare Gilead Sciences, Inc. (GILD) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Symbotic Inc — how do they compare? Gilead Sciences, Inc. trades at $133.1 (market cap $163.51B), while Symbotic Inc trades at $42.97 (market cap $5.42B). The key difference: Gilead Sciences, Inc. is far larger — about 30.2× Symbotic Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| GILD | SYM | |
|---|---|---|
Market Cap | $163.51B | $5.42B |
Sector | Health | Technology |
52-Week High | $155.80 | $87.30 |
52-Week Low | $108.22 | $38.57 |
Enterprise Value | $178.05B | $3.42B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SYM trades at $43.00, down 1.51% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported $2.25B revenue for 2025 but posted a net loss of $16.94M, though margins show improvement. Recent news highlights Symbotic's acquisition of ARMS Innovations and strong positioning in warehouse automation, with Amazon's robotics expansion potentially benefiting the company.
Analysts maintain a bullish consensus with a $57.50 price target (61% buy ratings), but near-term risks include negative profitability, high valuation multiples (EV/EBITDA 231.28), and competitive pressures. The stock faces technical resistance at $44-46 while testing support at $40-42, requiring improved earnings execution to justify current valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
